Results 31 to 40 of about 184,433 (313)
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND:
The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.Ferguson, J., Claudia Wellbrock, Erice, O., Margison, G.P., Goicoechea, I., Geoffrey P Margison, Margison, Geoffrey P, Wellbrock, C., Wellbrock, Claudia, Jennnifer Ferguson, Arozarena, Imanol, Goicoechea, Ibai, Imanol Arozarena, Ferguson, Jennnifer, Erice, Oihane, Oihane Erice, Ibai Goicoechea +16 morecore +1 more sourceCaveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models [PDF]
, 2014 Melanomas are highly lethal skin tumours that are frequently treated by surgical resection. However, the efficacy of such procedures is often limited by tumour recurrence and metastasis. Caveolin-1 (CAV1) has been attributed roles as a tumour suppressor, Bieneck, S, Muñoz, N, Quest, AF, Bennett, DC, Silva, V, Sviderskayae, Elena V., Lobos González, Lorena, Muñoz, Nicolás, Fernandez, JG, Silva, Verónica, Hossain, Mehnaz, Bennett, Dorothy C., Fernández Ruiz, Jaime Gonzalo, Quest, Andrew F. G., Burzio, V, Leyton, L, Quest, Andrew F.G., Lobos-Gonzalez, L, Bieneck, Simone, Sviderskaya, EV, Burzioc, Verónica, Aguilar Guzmán, Lorena, Hossain, M, Aguilar Guzmán, Lorena Andrea, Aguilar-Guzmán, L, Leyton Campos, Lisette +25 morecore +1 more sourceThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network [PDF]
, 2013 Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.Berking, Carola, Armin Justich (103646), Simone M. Goldinger, Daniela Göppner, Lucie M Heinzerling, Stephan Grabbe (103633), Clemens L. Bockmeyer, Robert Caroline, Thomas Eigentler, Christine Mateus (103663), Moos, Roger von, Loquai Carmen, Gerold Schuler, Dirk Schadendorf (103684), Christina Klein, Pätzold, Sylvie, Hundorfean, Gheorghe, Beatrice Schuler-Thurner, Göppner Daniela, Ralf Gutzmer (103628), Patrik Weder, Robert, Caroline, Bockmeyer, Clemens L., Dirk Schadendorf, Kaehler, Katharina C., Thomas Eigentler (103619), Katharina C. Kaehler, Gheorghe Hundorfean, Christine Mateus, Simone M. Goldinger (103594), Claus Garbe, Satzger, Imke, Ralf Gutzmer, Sylvie Paetzold (103676), Peter Mohr, Uwe Trefzer, Voskens, Caroline J, Carmen Loquai (103597), Bockmeyer Clemens L., Vaubel, Julia, Jens Ulrich, Wilhelm, Tabea, Bockmeyer, Clemens Luitpold, Julia Vaubel, Hauschild Axel, Mohr, Peter, Gheorghe Hundorfean (103642), Caroline J. Voskens, Justich, Armin, Hauschild, Axel, Fluck Michael, Loquai, Carmen, Schadendorf, Dirk, Beatrice Schuler-Thurner (103693), Satzger Imke, Göppner, Daniela, Carola Berking, Weder Patrik, Hundorfean Gheorghe, Eigentler, Thomas Kurt, Grabbe, Stephan, Ulrich Jens, Armin Justich, Rüdiger Hein (71354), Garbe Claus, Ulrich, Jens, Eigentler Thomas, Schadendorf Dirk, Gutzmer Ralf, Mateus Christine, Imke Satzger, Weder, Patrik, Ullrich Keller (103650), Lucie M. Heinzerling (103723), Gerold Schuler (103690), Axel Hauschild (103637), Christina Klein (103657), Michael Fluck, Tanja Bergmann (103612), Axel Hauschild, Paetzold Sylvie, Katharina C Kaehler, Wilhelm Tabea, Keller, Ullrich, Schlaeppi Marc, Goldinger, Simone M., Claus Garbe (48881), Berking Carola, Heinzerling, Lucie, von Moos Roger, Simone M Goldinger, Trefzer Uwe, Uwe Trefzer (72075), Rüdiger Hein, Mateus, Christine, Caroline Robert, Tabea Wilhelm (103712), Schuler Gerold, Dummer, Reinhard, Schuler-Thurner Beatrice, Roger von Moos, Hein Rüdiger, Eigentler, Thomas, Paetzold, Sylvie, Caroline J Voskens, Caroline J. Voskens (103590), Schuler-Thurner, Beatrice, Roger von Moos (103705), Patrik Weder (103709), Lucie M. Heinzerling, Kaehler, Katharina C, Voskens, Caroline J., Fluck, Michael, Imke Satzger (103681), Schuler, Gerold, Tanja Bergmann, Marc Schlaeppi (103687), Bergmann, Tanja Regina, Julia Vaubel (103700), Bergmann Tanja, Heinzerling, Lucie M., Stephan Grabbe, Klein Christina, Caroline Robert (103600), Carola Berking (103608), Kähler, Katharina C., Peter Mohr (103669), Klein, Christina, Tabea Wilhelm, Reinhard Dummer (103718), Goldinger Simone M., Reinhard Dummer, Marc Schlaeppi, Gutzmer, Ralf, Hein, Rüdiger, Clemens L Bockmeyer, Sylvie Paetzold, Michael Fluck (103622), Kaehler Katharina C., Justich Armin, Voskens Caroline J., Carmen Loquai, Vaubel Julia, Grabbe Stephan, Keller Ullrich, Mohr Peter, Jens Ulrich (103696), Trefzer, Uwe, Katharina C. Kaehler (103604), Bergmann, Tanja, Heinzerling Lucie M., Dummer Reinhard, et al, Goldinger, Simone M, Daniela Göppner (103715), Garbe, Claus, Clemens L. Bockmeyer (103616), Schlaeppi, Marc, Ullrich Keller +158 morecore +1 more sourceCost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France
Current Oncology, 2022 Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear.Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget +26 moredoaj +1 more sourcePembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Frontiers in Immunology, 2022 Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and limited therapeutic options.Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Haiyan Dai, Cuizhen Niu, Jianfeng Li, Jun Guo +17 moredoaj +1 more sourceAdjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [PDF]
, 2014 Background:
Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of ...N. Davidson (7671467), J. P. Nobes (7671491), P. Lorigan (7671500), Harries, M., C. G. Kelly (7671473), A. Marshall (7671452), M. R. Middleton (7671458), Dunn, Janet A, Houston, Stephen J, Board, Ruth E., Steve Nicholson (7671470), Lorigan, P., Waterston, A.M., Nobes, Jenny P., Gore, M.E., Kelly, Charles G, Danson, S., Nathan, Paul D, Nathan, Paul D., Kumar, S., Middleton, Mark R., Davidson, Neville, Marples, M., Nobes, Jenny P, Waterston, Ashita M, Young, G., Dunn, J., Nathan, P.D., Lorigan, Paul; id_orcid, Houston, S., Danson, Sarah J, M. Gore (7671464), Davidson, D., Board, R.E., M. Marples (7671476), Dunn, Janet A., Nobes, J.P., Marshall, E., Corrie, P., S. J. Danson (7671479), Marshall, A., Middleton, Mark R, Board, Ruth E, Middleton, M.R., Marshall, Ernest, Gore, Martin, Marples, Maria, Corrie, Pippa G, P. D. Nathan (7671461), G Young (7671497), E. Marshall (7241588), Houston, Stephen J., Young, Gemma, Nicholson, Steve, A. M. Waterston (7671488), Kelly, Charles G., P. G. Corrie (7671449), S. J. Houston (7671482), Kelly, C.G., Corrie, Pippa G., M. Harries (7671494), Marshall, Andrea, Kumar, Satish, S. Kumar (746162), Nicholson, S., Waterston, Ashita M., R. E. Board (7671485), Harries, Mark, Danson, Sarah J., Marshall, A. (Andrea), Lorigan, Paul, J. A. Dunn (7671455) +71 morecore +1 more sourceAssociation of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Frontiers in Medicine, 2019 Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced ...Taku Fujimura, Yota Sato, Kayo Tanita, Chunbing Lyu, Yumi Kambayashi, Ryo Amagai, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Hiroo Hata, Takeru Funakoshi, Yumi Nonomura, Ryota Tanaka, Hisako Okuhira, Naoko Wada, Akira Hashimoto, Setsuya Aiba +19 moredoaj +1 more source
